Cognition Therapeutics

Cognition Therapeutics

Cognition Therapeutics is developing new drugs to treat and prevent symptoms in neurodegenerative disorders. CogRx’s proprietary small molecule drugs are the first ever reported to target toxic receptors and pathways central to the pathology of Alzheimer’s disease, reversing memory deficits and blocking disease progression. Founded in 2007, the Company is working to take these drug candidates to the next level with clinical trials.

Investment Info
Cowtown Investment: $350,000

Total Raised in Series: $1,000,000

Website